Journal
ANTIVIRAL RESEARCH
Volume 119, Issue -, Pages 19-22Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.antiviral.2015.04.006
Keywords
Severe Fever with Thrombocytopenia Syndrome; Ribavirin; Adverse event; Hyperamylasemia
Categories
Funding
- China Mega-Project for Infectious Diseases [2013ZX10004-202]
- Natural Science Foundation of China [81222037, 81473023]
- Youth Talent Support Program by School of Public Health, Peking University
Ask authors/readers for more resources
Severe Fever with Thrombocytopenia Syndrome (SFTS) is associated with high mortality rate, for which antiviral therapy with ribavirin was recommended. Based on our previous study, no visible effect of ribavirin therapy in improving clinical outcome was observed. Here we have accumulated the sample size to 634, and by performing prospective observation on the clinical progress and laboratory parameters, we found a significantly higher incidence of anemia and hyperamylasemia in patients who received ribavirin therapy in comparison with those who received no therapy. Generalized estimating equation model disclosed a significant effect on hemoglobin reduction and blood amylase augmentation from ribavirin administration. The occurrence of anemia and hyperamylasemia was associated with SFTS patients receiving ribavirin therapy, which might be adverse event of this drug administration. The recommendation of ribavirin for treating SFTS should be applied with caution. (C) 2015 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available